Lowering E2F1 expression or blocking the deleterious E2F1-STAT3/IL-6 axis to modulate the tumor secretome could therefore improve antitumor responses and reduce adverse effects when interleukins and ICIs are used in combination. This evidence concerns the gene E2F1 and neoplasm.